Cargando…
Parenchymal central nervous system involvement in aggressive B-cell lymphoma: retrospective analysis of clinical and MRI features in a Chinese population
BACKGROUND: Secondary central nervous system lymphoma (SCNSL) is defined as secondary central nervous system (CNS) involvement in patients with systemic lymphoma. It is considered a profoundly adverse complication with inferior clinical outcome. Parenchymal involvement in the CNS in aggressive B-cel...
Autores principales: | Wu, Yuchen, Wang, Yaming, Sun, Xuefei, Bai, Xueyan, Qian, Jun, Zhu, Hong, Cui, Qu, Xing, Ruixian, Chen, Yuedan, Liu, Qing, Guo, Jiayuan, Ji, Nan, Sun, Shengjun, Liu, Yuanbo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6829840/ https://www.ncbi.nlm.nih.gov/pubmed/31684888 http://dx.doi.org/10.1186/s12883-019-1511-3 |
Ejemplares similares
-
Treatment of secondary central nervous system involvement in systemic aggressive B cell lymphoma using R-MIADD chemotherapy: a single-center study
por: Wu, Yuchen, et al.
Publicado: (2021) -
Expression of hypoxia‐inducible factor 1α, glucose transporter 1, and hexokinase 2 in primary central nervous system lymphoma and the correlation with the biological behaviors
por: Shen, Na, et al.
Publicado: (2020) -
Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma
por: Sun, Xuefei, et al.
Publicado: (2017) -
Interstitial pneumonitis during rituximab-containing chemotherapy for primary central nervous system lymphomas: a case report and review of literature
por: Wu, Yuchen, et al.
Publicado: (2018) -
Non-Myeloablative Chemotherapy as Consolidation Strategy After High-Dose Methotrexate-Based Chemoimmunotherapy in Patients With Primary CNS Lymphoma: A Retrospective Single Center Study in China
por: Sun, Xuefei, et al.
Publicado: (2022)